See more : SK Telecom Co.,Ltd (SKM) Income Statement Analysis – Financial Results
Complete financial analysis of Assertio Holdings, Inc. (ASRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Assertio Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- JSC National Atomic Company Kazatomprom (KAP.IL) Income Statement Analysis – Financial Results
- The Goldman Sachs Group, Inc. (GS-PJ) Income Statement Analysis – Financial Results
- Barloworld Limited (BAW.JO) Income Statement Analysis – Financial Results
- Zensho Holdings Co., Ltd. (7550.T) Income Statement Analysis – Financial Results
- Precipio, Inc. (PRPO) Income Statement Analysis – Financial Results
Assertio Holdings, Inc. (ASRT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.assertiotx.com
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 152.07M | 156.23M | 111.01M | 106.28M | 229.50M | 311.77M | 380.72M | 455.90M | 342.74M | 390.36M | 134.21M | 90.82M | 132.97M | 80.76M | 57.73M | 34.84M | 65.58M | 9.55M | 4.41M | 202.57K | 981.99K | 1.66M | 3.67M | 1.78M | 115.33K | 800.00K | 600.00K | 300.00K |
| Cost of Revenue | 27.02M | 18.75M | 15.83M | 19.87M | 9.51M | 18.48M | 72.60M | 87.41M | 67.90M | 15.15M | 7.09M | 6.04M | 5.54M | 8.10M | 5.26M | 5.77M | 2.60M | 1.60M | 908.52K | 0.00 | 0.00 | 0.00 | 0.00 | -561.76K | -643.49K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 125.05M | 137.49M | 95.18M | 86.40M | 220.00M | 293.29M | 308.13M | 368.48M | 274.84M | 375.22M | 127.11M | 84.78M | 127.43M | 72.67M | 52.47M | 29.07M | 62.99M | 7.95M | 3.50M | 202.57K | 981.99K | 1.66M | 3.67M | 2.34M | 758.82K | 1.30M | 800.00K | 300.00K |
| Gross Profit Ratio | 82.23% | 88.00% | 85.74% | 81.30% | 95.86% | 94.07% | 80.93% | 80.83% | 80.19% | 96.12% | 94.72% | 93.35% | 95.83% | 89.97% | 90.89% | 83.43% | 96.04% | 83.24% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | 131.63% | 657.97% | 162.50% | 133.33% | 100.00% |
| Research & Development | 2.84M | 0.00 | 0.00 | 4.21M | 10.11M | 8.04M | 38.62M | 32.63M | 72.44M | 7.12M | 8.07M | 15.46M | 15.19M | 20.11M | 34.30M | 27.27M | 23.34M | 26.89M | 18.37M | 21.36M | 26.90M | 24.71M | 15.46M | 7.49M | 3.73M | 2.10M | 900.00K | 400.00K |
| General & Administrative | 65.34M | 43.39M | 54.76M | 103.92M | 108.07M | 118.42M | 192.00M | 200.40M | 197.05M | 119.33M | 105.18M | 97.65M | 54.21M | 17.51M | 16.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 4.40M | 3.40M | 1.80M | 400.00K | 800.00K | 800.00K | 3.70M | 4.10M | 2.30M | 1.80M | 2.40M | 1.50M | 27.34M | 31.42M | 23.59M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.64M | 46.79M | 56.56M | 104.32M | 108.87M | 119.22M | 195.70M | 204.50M | 199.35M | 121.13M | 105.18M | 97.65M | 81.54M | 48.93M | 40.25M | 26.40M | 26.69M | 22.67M | 11.64M | 5.18M | 3.48M | 5.37M | 2.53M | 2.03M | 1.87M | 2.00M | 1.00M | 400.00K |
| Other Expenses | 287.10M | 32.61M | 28.11M | 24.78M | 101.77M | 101.77M | 102.75M | 106.85M | 599.00K | 10.16M | -249.00K | 481.00K | 0.00 | 0.00 | 0.00 | -7.50M | -34.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| Operating Expenses | 368.59M | 79.39M | 84.67M | 133.32M | 220.75M | 229.03M | 337.06M | 343.97M | 355.14M | 138.40M | 117.80M | 115.13M | 96.73M | 69.04M | 74.54M | 46.17M | 15.45M | 49.56M | 30.01M | 26.54M | 30.38M | 30.09M | 17.99M | 10.08M | 6.25M | 4.60M | 2.10M | 800.00K |
| Cost & Expenses | 395.61M | 98.14M | 100.50M | 153.19M | 230.25M | 247.51M | 409.66M | 431.39M | 423.04M | 153.55M | 124.89M | 121.17M | 102.28M | 77.14M | 79.80M | 51.94M | 18.04M | 51.16M | 30.92M | 26.54M | 30.38M | 30.09M | 17.99M | 9.51M | 5.61M | 4.10M | 1.90M | 800.00K |
| Interest Income | 0.00 | 7.96M | 10.22M | 15.93M | 58.39M | 1.20M | 681.00K | 485.00K | 599.00K | 215.00K | 662.00K | 520.00K | 557.00K | 839.00K | 1.05M | 2.35M | 2.27M | 2.03M | 1.45M | 489.01K | 299.14K | 101.11K | 0.00 | 222.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.38M | 7.96M | 10.22M | 15.93M | 58.39M | 68.88M | 73.55M | 83.72M | 73.44M | 23.92M | 4.49M | 39.00K | 133.00K | 572.00K | 1.00M | 555.00K | 0.00 | 0.00 | 459.74K | 928.88K | 910.42K | 732.57K | 105.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.23M | 33.41M | 29.11M | 26.38M | 102.97M | 106.43M | 105.50M | 109.38M | 83.34M | 10.16M | 4.55M | 2.02M | 420.00K | 439.00K | 808.00K | 1.15M | 865.00K | 1.38M | 1.14M | 1.70M | 1.04M | 745.14K | 610.81K | 561.76K | 643.49K | 500.00K | 200.00K | 0.00 |
| EBITDA | -222.45M | 72.54M | 38.78M | -3.20M | -61.12M | 213.16M | 74.05M | 133.76M | 35.94M | 252.64M | 16.68M | -27.27M | 71.68M | 4.90M | -20.21M | -13.60M | 48.40M | -40.23M | -25.37M | -24.63M | -28.35M | -27.68M | -13.71M | -7.18M | -4.85M | -2.84M | -1.00M | -500.00K |
| EBITDA Ratio | -146.28% | 58.38% | 35.88% | -23.86% | 45.74% | 53.64% | 19.57% | 28.92% | 1.06% | 63.32% | 10.15% | -31.20% | -7.00% | 5.53% | -36.42% | -67.30% | 21.07% | -421.17% | -599.99% | -12,160.55% | -2,887.38% | -2,749.98% | -373.25% | -280.87% | 6,215.39% | -412.50% | -183.33% | -166.67% |
| Operating Income | -243.54M | 57.81M | 9.42M | -46.92M | 3.20M | 43.66M | -42.18M | 24.51M | -50.40M | 236.81M | 9.32M | -30.35M | 70.70M | 3.63M | -22.07M | -17.10M | 47.54M | -41.61M | -26.51M | -26.33M | -29.40M | -28.43M | -14.32M | -7.74M | -5.49M | -3.30M | -1.30M | -500.00K |
| Operating Income Ratio | -160.15% | 37.00% | 8.49% | -44.15% | 1.39% | 14.00% | -11.08% | 5.38% | -14.71% | 60.67% | 6.94% | -33.42% | 53.17% | 4.49% | -38.23% | -49.06% | 72.49% | -435.62% | -601.81% | -13,000.40% | -2,993.76% | -1,711.27% | -389.88% | -435.66% | -4,760.78% | -412.50% | -216.67% | -166.67% |
| Total Other Income/Expenses | -10.52M | -26.65M | -9.98M | 36.64M | -28.06M | -5.68M | -61.75M | -89.01M | -72.84M | -23.71M | -4.74M | 481.00K | 424.00K | 267.00K | 49.00K | 1.79M | 39.56M | 2.03M | 2.04M | -439.87K | -5.36K | 15.56M | -3.17M | -2.19M | -12.02M | 536.86K | 0.00 | 500.00K |
| Income Before Tax | -254.05M | 31.17M | -553.00K | -45.51M | -222.48M | 37.98M | -103.92M | -64.50M | -123.24M | 213.11M | 4.58M | -29.87M | 71.12M | 3.89M | -22.02M | -15.30M | 49.81M | -39.58M | -24.47M | -26.77M | -29.40M | -12.86M | -17.49M | -9.93M | -17.51M | -2.80M | 0.00 | 0.00 |
| Income Before Tax Ratio | -167.06% | 19.95% | -0.50% | -42.83% | -96.94% | 12.18% | -27.30% | -14.15% | -35.96% | 54.59% | 3.41% | -32.89% | 53.49% | 4.82% | -38.15% | -43.92% | 75.95% | -414.36% | -555.40% | -13,217.54% | -2,994.31% | -774.33% | -476.27% | -558.82% | -15,178.98% | -350.00% | 0.00% | 0.00% |
| Income Tax Expense | 77.89M | -78.46M | 728.00K | -17.37M | -5.28M | 1.07M | -1.43M | 24.22M | -47.50M | 81.35M | -38.73M | -91.00K | 396.00K | -4.00K | -15.00K | 1.00K | 592.00K | 82.50K | -2.04M | 99.00K | 611.28K | -17.37M | 105.20K | 1.96M | 11.72M | -500.00K | -100.00K | 500.00K |
| Net Income | -331.94M | 109.63M | -1.28M | -28.14M | -217.20M | 36.91M | -102.50M | -88.72M | -75.74M | 131.76M | 43.31M | -29.78M | 70.73M | 3.90M | -22.01M | -15.30M | 49.22M | -39.66M | -24.47M | -26.87M | -30.02M | -13.49M | -17.60M | -9.70M | -17.21M | -2.80M | -1.20M | -500.00K |
| Net Income Ratio | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | 11.84% | -26.92% | -19.46% | -22.10% | 33.75% | 32.27% | -32.79% | 53.19% | 4.82% | -38.12% | -43.92% | 75.05% | -415.23% | -555.40% | -13,266.41% | -3,056.56% | -812.35% | -479.13% | -546.27% | -14,921.74% | -350.00% | -200.00% | -166.67% |
| EPS | -4.67 | 2.33 | -0.03 | -1.07 | -12.29 | 2.31 | -6.54 | -5.80 | -5.04 | 9.04 | 3.04 | -2.13 | 5.20 | 0.28 | -1.71 | -1.25 | 4.24 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| EPS Diluted | -4.67 | 2.01 | -0.03 | -1.07 | -12.29 | 2.30 | -6.54 | -5.79 | -5.04 | 8.20 | 3.00 | -2.13 | 5.04 | 0.28 | -1.71 | -1.25 | 4.20 | -3.82 | -2.46 | -3.10 | -4.91 | -3.69 | -6.89 | -5.29 | -10.63 | -1.77 | -1.08 | -0.48 |
| Weighted Avg Shares Out | 71.03M | 47.00M | 43.17M | 26.21M | 17.68M | 15.95M | 15.68M | 15.30M | 15.03M | 14.57M | 14.18M | 13.97M | 13.64M | 13.13M | 12.88M | 12.19M | 11.49M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
| Weighted Avg Shares Out (Dil) | 71.03M | 54.67M | 43.17M | 26.21M | 17.68M | 16.05M | 15.68M | 15.32M | 15.03M | 16.58M | 14.39M | 13.97M | 14.02M | 13.34M | 12.88M | 12.19M | 11.59M | 10.38M | 9.96M | 8.66M | 6.11M | 3.66M | 2.56M | 1.83M | 1.62M | 1.58M | 1.11M | 1.04M |
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - ASRT
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT). The class action, filed in the United States District Court for...
ASRT LAWSUIT ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / March 3, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT
NEW YORK, NY / ACCESSWIRE / March 2, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings Lawsuit - ASRT
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Class Action Filed Against Assertio Holdings, Inc. (ASRT) - March 5, 2024 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Assertio Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 5, 2024 - ASRT
NEW YORK, NY / ACCESSWIRE / March 1, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Assertio Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights – ASRT
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Source: https://incomestatements.info
Category: Stock Reports